UK & Europe

AMG Critical Materials posted $44m adjusted EBITDA in Q1 2026, ahead of guidance, driven by vanadium gains and the AURA acquisition.

Greenwich LifeSciences has pushed its 2025 annual filing to May while reporting a 70–80% recurrence reduction in preliminary Phase III open-label data.

The Geneva-based allosteric modulator specialist ended 2025 with thinning cash reserves but two Phase 2 assets in hand after regaining rights to ADX71149.

The Copenhagen biotech and its Roche partner will advance their once-weekly amylin analog into Phase 3 obesity trials after Phase 2 showed double-digit

The Lyon-based vaccine specialist raised €37m at closing, with up to €47m more if warrants tied to FDA Lyme approval are exercised.

Tempest will share updated REDEEM-1 Phase 1/2a results for its CD19/BCMA dual-targeting CAR-T in relapsed/refractory myeloma at Dublin's

The Berlin biotech selected TCX-201 as its first clinical candidate and targets a CTA filing in 2027 for gastrointestinal and solid tumours.

The Fort Lauderdale biotech reported an 87% overall response rate in a 15-patient Phase 1 study and is advancing to Phase 2 in metastatic

The Swiss rare-disease pharma is putting the former Idorsia CEO forward as an independent director at its 26 May annual general meeting.

The Nantes-based biotech reported a sharp swing to loss in 2025 and warned auditors may issue a going concern qualification absent new financing.

OTL-201, an HSC gene therapy for the fatal childhood disorder Sanfilippo syndrome type A, is one of the first three therapies designated under the

Phase 2 data presented at IPCS 2026 show low off-target radiation, supporting dose intensification and a new mHSPC trial for Telix's next-generation

The French ophthalmology biotech doubled revenue to €16.8m in 2025 and expects to file its glaucoma candidate NCX 470 with the FDA by summer

Mesoblast has hit its 300-patient recruitment target for MSB-DR004, with topline data expected mid-2027 ahead of a planned FDA BLA filing.

CorTec's Brain Interchange device delivered both stroke rehabilitation and thought-based computer control in one patient using identical implanted hardware.

its a long test to see what having a sponsored post looks like when publoshed.

On this week's episode of News & Views, The Fintech Times Podcast team speak about crypto scam losses exceeding $4billion in 2024